They suggested that acetylcarnitine can be considered a metabolomic biomarker complementary to alpha-fetoprotein levels in patients with HCC [30] and attributed reduced levels of acetylcarnitine in HCC patients to the reduced levels of carnitine observed in cancer cachexia [30,31,32]. This evidence concerns the gene AFP and hepatocellular carcinoma.